Clinical Trials Logo

Clinical Trial Summary

Context: Therapeutic plasma exchange is an extracorporeal blood purification technique that removes pathogenic substances (including antibodies) from plasma. This technique also combines an immunomodulatory effect. The impact on the anti-SARS-CoV-2 titre and the humoral and cellular responses in the general population benefiting from therapeutic plasma exchanges is not known at this time. The purpose of this study is to evaluate the evolution of anti-SARS-CoV-2 antibodies' titre over time in vaccinated adult patients treated with therapeutic plasma exchange. Research question and associated variables: Prospective non-drug interventional study on the possible variation of anti-SARS-CoV-2 antibody titre in adult patients regularly treated with therapeutic plasma exchange. Study population: any adult patient vaccinated against SARS-CoV-2 (any type of vaccine) and regularly receiving therapeutic plasma exchange in the adult hematology department of the Cliniques universitaires Saint Luc in Brussels, Belgium. Number of subjects expected to be enrolled: 10-15

Clinical Trial Description

Not provided ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05191394
Study type Interventional
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Status Completed
Phase N/A
Start date September 8, 2021
Completion date February 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04685655 - RescuE pLAsma eXchange in Severe COVID-19 N/A
Active, not recruiting NCT04351438 - Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation
Active, not recruiting NCT03888417 - TPE in Rennes Hospital